Elsiglutide (ZP 1846) is a synthetic 39-amino acid glucagon-like peptide-2 (GLP-2) analogue. Upon subcutaneous administration, elsiglutide binds to GLP-2 receptors and thereby promotes proliferation of epithelial cells. Elsiglutide prevents or reduces the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID). Elsiglutide is being developed by Helsinn Healthcare, for the prevention of chemotherapy-induced diarrhoea.

Lenomorelin (Ghrelin) is a pleiotropic hormone, whose effect on growth hormone secretion, through the growth hormone secretagogue (GHS) receptor, is one of its many actions. It is synthesized principally in the stomach. Ghrelin-producing cells constitute a distinct group of endocrine cells dispersed throughout the gastric mucosa and to a lesser extent in the small intestine and the endocrine pancreas. Ghrelin plasma levels rise during fasting and chronic caloric restriction to stimulate food intake and fat storage and to prevent life-threatening falls in blood glucose. Plasma ghrelin levels decrease after a meal is consumed and in conditions of energy surplus (such as obesity). Ghrelin has emerged as a key player in the regulation of appetite and energy homeostasis. It stimulates food intake and transduces signals to hypothalamic regulatory nuclei that control energy homeostasis. Ghrelin levels are negatively correlated with body mass index (BMI) and insulin resistance. Lenomorelin is a peptide of 28 amino acids, in which the serine 3 residue is n-octanoylated, which is necessary for biological activity.

Aspartocin, an antibiotic, possesses antimicrobial properties

Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.

Dumorelin is a 27-L-Leu-44a-Gly peptide. It is a stimulator of human growth hormone release.

Dirucotide (MBP 8298) is a synthetic myelin basic protein (MBP) peptide designed to decrease type 2 helper T cells (TH2)-mediated B-cell signalling of auto-reactive T-cells thereby reducing the production of specific antibodies that target endogenous MBP. MBP is the dominant site of attack in patients with multiple sclerosis and haplotype (HLA) DR2 or DR4. Dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. After disappointing trial results, development of the drug was ended in 2009.